Radiopharm Theranostics Limited American Depositary Shares (NASDAQ:RADX) — Market Cap & Net Worth
Market Cap & Net Worth: Radiopharm Theranostics Limited American Depositary Shares (RADX)
Radiopharm Theranostics Limited American Depositary Shares (NASDAQ:RADX) has a market capitalization of $34.06 Million ($34.06 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23385 globally and #5027 in its home market, demonstrating a 4.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Radiopharm Theranostics Limited American Depositary Shares's stock price $4.41 by its total outstanding shares 7883165 (7.88 Million). Review RADX current and long-term liabilities to assess the company's total debt and financial obligations.
Radiopharm Theranostics Limited American Depositary Shares Market Cap History: 2026 to 2026
Radiopharm Theranostics Limited American Depositary Shares's market capitalization history from 2026 to 2026. Data shows growth from $34.76 Million to $34.76 Million (0.00% CAGR).
Radiopharm Theranostics Limited American Depositary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Radiopharm Theranostics Limited American Depositary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RADX by Market Capitalization
Companies near Radiopharm Theranostics Limited American Depositary Shares in the global market cap rankings as of June 17, 2026.
Key companies related to Radiopharm Theranostics Limited American Depositary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Radiopharm Theranostics Limited American Depositary Shares Historical Marketcap From 2026 to 2026
Between 2026 and today, Radiopharm Theranostics Limited American Depositary Shares's market cap moved from $34.76 Million to $ 34.76 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $34.76 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Radiopharm Theranostics Limited American Depositary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $34.06 Million USD |
| MoneyControl | $34.06 Million USD |
| MarketWatch | $34.06 Million USD |
| marketcap.company | $34.06 Million USD |
| Reuters | $34.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more